Finance entity
Every one of those 1 sits in a single category, earnings. PYLARIFY is most often covered alongside Heron Therapeutics, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. PYLARIFY is most often covered alongside Heron Therapeutics, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. The 5 average consequence score is below the beat benchmark of 6 in the same window. PYLARIFY appears in 1 tracked Finance story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PYLARIFY. Shared-story counts are live from our verified record — not editorial picks.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
PYLARIFY is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
